Repinotan in Patients With Acute Ischemic Stroke

Completed

Phase 2 Results

Summary of Purpose

The purpose of this trial is to evaluate Repinotan HCl in patients with acute ischemic stroke. At study entry patients will be randomized to Repinotan HCl or placebo in a 1:1 ratio. The total treatment period wil be 72 hours.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 9 June 2009.

1 Dec 2000 6 Sep 2002 Unavailable 1 Sep 2004 1 Jun 2009 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

Not available